logo
Why do some creatives prefer working in the dark?

Why do some creatives prefer working in the dark?

If you find yourself inspired and productive in a dark room by the faint glow of a lamp, you are not alone. (Envato Elements pic)
Imagine it's either early in the morning or late at night. The room is dark, your computer screen glows in the darkness, and your surroundings are quiet.
Whether you are a writer, designer or artist, you might flourish as a creative person in these low-key settings. But why? Is this preference based on scientific or psychological grounds, or is it merely a quirk of the imaginative brain?
Studies have shown that our brain's capability to process information and generation thought can be affected by the brightness (or otherwise) of a room.
Research in the Journal of Environmental Psychology suggests that reduced lighting levels can boost cognitive flexibility, facilitating creative thinking. Meanwhile, a German study posits that 'darkness increases freedom from constraints, which in turn promotes creativity'.
Bright surroundings, on the other hand, are often linked with analytical and ordered thinking, which may not always be perfect for artistic activities.
Specifically, working in the dark lessens visual distractions, allowing the brain to concentrate more closely on current tasks. This can cause a condition known as 'flow', in which creative professionals get engrossed in their work with fewer interruptions.
Darkness and the subconscious
As the German research notes, low brightness fosters psychological freedom: people frequently feel less self-conscious in darkness, which helps reduce obstructions and inspires more unique thoughts. Some people are more at ease sharing their ideas in a quiet, private environment than under intense, fluorescent light.
Combining natural light throughout the day with low lighting in the evening may help you maximise your creative process. (Envato Elements pic)
Moreover, the atmosphere of a low-light workspace affects emotions and mood. Warm, low lighting can assist creatives in controlling their stress by encouraging peace and relaxation.
This is why many musicians, writers, and artists choose to work at night – not only for the silence but also for the mood the darkness creates.
So, the final question is: does this work for everyone?
Although many artists swear by the dark, it is not a one-size-fits-all solution. For some people, poor brightness can cause them to feel lazy or drowsy. Others encounter eye strain from staring at a screen in a dark room.
The secret is balance. Try several lighting setups to see which improves your well-being and output. Combining natural light throughout the day with low lighting in the evening may help you maximise your creative process.
Ultimately, the joy of working in the dark among creatives is real, regardless of scientific backing or personal inclination. You are not alone if you find the most inspiration in shadows and the faint glow of your desk lamp or screen.
This article was originally written by Anisa Aznan for jobstore.com, an online job site that specialises in providing jobseekers with the latest job opportunities by matching talented individuals with reputable companies in Malaysia. Find your dream job with over 40,000 job vacancies in Malaysia.
Read more articles from Jobstore here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties
Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties

Malay Mail

time2 days ago

  • Malay Mail

Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties

FRANKFURT, Aug 8 — American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday. The royalties would amount to a 'single-digit' percentage on sales of Covid-19 vaccines in the United States, CureVac said. The German firm added that it would grant Pfizer and BioNTech non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States. GSK, which since 2020 has worked with CureVac to develop mRNA vaccines for infectious diseases, said that it would receive US$370 million as well as a one-per cent royalty on US sales of flu, Covid and 'related combination mRNA vaccine products'. CureVac sued German rival BioNTech in 2022, arguing that BioNTech had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in colloboration with Pfizer. Unlike traditional vaccines which contain some form of the dead or inactivated target virus,mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines. The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. CureVac's own efforts to make an mRNA-based covid vaccine during the pandemic did not come to fruition. The deal brings the dispute between CureVac and BionNTech to an end ahead of the planned acquisition of CureVac by BioNTech, announced in June. CureVac and BioNTech are still locked in legal disputes in Germany but CureVac said the deal 'set a framework for resolving ongoing patent disputes outside the US'. In March, a German court sided with American pharmaceutical firm Moderna in its claim that BioNTech and Pfizer had broken one of its patents in making its Covid-19 vaccine. — AFP

It's not just in your head: UK scientists identify genetic links to chronic fatigue syndrome in breakthrough study
It's not just in your head: UK scientists identify genetic links to chronic fatigue syndrome in breakthrough study

Malay Mail

time3 days ago

  • Malay Mail

It's not just in your head: UK scientists identify genetic links to chronic fatigue syndrome in breakthrough study

LONDON, Aug 7 — Researchers at the University of Edinburgh said yesterday they have discovered differences in the DNA of people with chronic fatigue syndrome that should help dispel the notion that the debilitating condition is psychological or driven by laziness. Their study found eight areas of genetic code that are different in people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) than in healthy volunteers. The finding provides 'the first robust evidence that genes contribute to a person's chance of developing the disease,' the researchers said in a statement. The key features of the condition include worsening of fatigue, pain and brain fog after even minor physical or mental activity. Very little has been known about the causes of ME/CFS, and there is no diagnostic test or cure. The condition is believed to affect around 67 million people worldwide, the researchers said. The DecodeME study analysed DNA samples from 15,579 people who reported having chronic fatigue on a questionnaire and 259,909 people without it, all of European descent. Gene variants that were more common in people reporting ME/CFS were linked to the immune and nervous systems, according to a report of the study that has not yet been peer-reviewed. At least two of the gene regions relate to how the body responds to infection, which aligns with reports that the symptoms often start after an infectious illness, the researchers said. Another gene region has previously been identified in people with chronic pain, another common symptom of the condition. The findings 'align with decades of patients reporting on their experiences,' researcher Andy Devereux-Cooke said in a statement, adding that they 'should prove game changing in the ME/CFS research field.' 'These results will not mean that a test or cure will be developed straight away, but they will lead to a greater understanding,' he said. Scientists who were not involved in the study said using volunteers who self-reported chronic fatigue syndrome rather than restricting participation to those with a diagnosis from a medical professional somewhat weakened its conclusions. They called for larger studies to replicate the results. Substantial work will be necessary 'to translate these findings into new treatments,' said Dr. Jackie Cliff, who studies infection and immunity in ME/CFS at Brunel University of London. 'This will take considerable investment in academia and by industry.' — Reuters

Pfizer Romania recognized as a Best Place to Work for 2025
Pfizer Romania recognized as a Best Place to Work for 2025

Malay Mail

time4 days ago

  • Malay Mail

Pfizer Romania recognized as a Best Place to Work for 2025

Leadership & Trust 94% of employees say leaders respect labor laws 89% believe leaders act with integrity and ethics 86% agree leadership communicates a clear and inspiring vision Culture of Inclusion 94% say differences (gender, ethnicity, age) do not affect how people are treated 90% feel their ideas and opinions are respected 91% say integrity is a shared value across teams Managerial Support 93% say their manager upholds ethical standards 90% feel supported in health and well-being 88% receive meaningful feedback to grow Engagement & Purpose 86% overall employee satisfaction 86% align with Pfizer's commitment to social responsibility 83% rate HR practices as people-focused 94% alignment with best practices in people-focused HR policies 90% alignment in leadership support and strategic direction 89% alignment in employee engagement initiatives 88% alignment in teamwork and cross-functional collaboration 81% alignment with best practices in benefits programs 73% alignment in compensation structures and fairness 93% alignment in community involvement and corporate social responsibility, reinforcing Pfizer's strong commitment to societal impact BUCHAREST, ROMANIA - Media OutReach Newswire - 6 August 2025 - Pfizer Romania has been officially certified as one of the, a recognition that highlights its commitment to fostering a workplace culture grounded in integrity, inclusion, and employee is a leading international certification that honors organizations providing exceptional employee experiences. The evaluation combines anonymous employee feedback with a comprehensive HR assessment, measuring areas such as leadership, culture, well-being, growth opportunities, and people Romania's certification was driven by impressive scores across key dimensions of workplace culture. According to the internal employee survey:In addition to the strong employee feedback,, which benchmarks the company's practices against recognized global standards. The results reflect how closely Pfizer Romania's approach aligns with best-in-class HR practices across multiple areas:said, General Manager of Pfizer Romania., Senior Manager, People Experience, added:Hashtag: #BestPlacesToWork The issuer is solely responsible for the content of this announcement. About Pfizer Romania Pfizer Romania, a subsidiary of Pfizer Inc., has been serving Romanian communities for over 30 years, delivering innovative medicines and vaccines across multiple therapeutic areas. Guided by the global mission "Breakthroughs that change patients' lives," the company collaborates closely with healthcare providers and institutions to expand access to quality healthcare and advance public health outcomes. About the Best Places to Work Program Best Places to Work is a global HR certification program that identifies leading employers around the world. The certification process includes a rigorous evaluation of workplace culture through employee surveys and an audit of HR practices across eight key areas, including leadership, well-being, inclusion, and career development. Learn more at: LinkedIn: Best Places to Work

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store